51
Participants
Start Date
May 31, 2013
Primary Completion Date
August 31, 2013
Study Completion Date
August 31, 2013
CR845
CR845 dosage = 0.005 mg/kg per dose, IV bolus. The initial dose was administered upon reaching a qualifying pain intensity score and followed by a supplemental dose, if requested by patient for pain. Additional doses could be administered every 8 hours up to 48 hours.
Placebo
Matching placebo administered using same dosing algorithm as the active arm
Jean Brown Research, Salt Lake City
Lead Sponsor
Cara Therapeutics, Inc.
INDUSTRY